# Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Participants With B-cell Malignancies

> **NCT04170283** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **BeiGene** · enrollment: 955 (actual)

## Conditions studied

- B-cell Malignancies

## Interventions

- **DRUG:** Zanubrutinib
- **DRUG:** Tislelizumab

## Key facts

- **NCT ID:** NCT04170283
- **Lead sponsor:** BeiGene
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-01-16
- **Primary completion:** 2027-11
- **Final completion:** 2028-12
- **Target enrollment:** 955 (ACTUAL)
- **Last updated:** 2025-10-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04170283

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04170283, "Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Participants With B-cell Malignancies". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT04170283. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*